Literature DB >> 32314313

Is COVID-19 a proteiform disease inducing also molecular mimicry phenomena?

Francesco Cappello1.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32314313      PMCID: PMC7167495          DOI: 10.1007/s12192-020-01112-1

Source DB:  PubMed          Journal:  Cell Stress Chaperones        ISSN: 1355-8145            Impact factor:   3.667


× No keyword cloud information.
It is evident that COVID-19, the disease due to severe acute respiratory syndrome coronavirus 2 (commonly abbreviated SARS-CoV-2) etiological agent, is not uniquely a respiratory disease, at least in a subset of patients. It is possible that we are facing a “proteiform” disease (from Proteus, the sea god who could change shape to avoid capture). As other coronavirus-induced infections, it initially affects the upper airways, but can move abruptly to the lower respiratory tract. Lastly, while physicians treat the bilateral lung pneumonia of their patients, systemic complications can appear characterized by thrombosis, disseminated intravascular coagulation and multi-organ failure. Health systems worldwide are now facing three major problems: 1) to identify asymptomatic carriers of infection; 2) to give effective home care to symptomatic people; 3) to properly stage hospitalized patients to avoid overwhelming numbers in intensive care units. This last group of patients experience, among other clinical signs, very low pO2 blood concentrations due to the destruction of lung parenchyma and massive activation of both innate and acquired immune responses. Presently, only ex juvantibus treatments are done in the most severe cases, since we are far from understanding what primes the systemic vascular complications. The term ex juvantibus or sometimes “ex adiuvantibus” from Latin, meaning “from that which helps” refers, in medical contexts, to the process of making an inference about disease causation from an observed response. I have a modest proposal that I would like to share with our readers. After studying the published clinical reports, what surprised me is that most patients who had the most severe complications were affected by two comorbidities (or their long-term effects): hypertension and diabetes. Both of them induce, among other problems, chronic stress on endothelial cells that in turn can express molecules on their plasma membranes abnormally as an effect of post-translational modifications of intracellular proteins, including some heat shock proteins. This condition can predispose cells and tissues to molecular mimicry phenomena that may occur during an infection (Cappello et al. 2009; Delunardo et al. 2013; Kotlarz et al. 2013; Mayr et al. 1999; Sun et al. 2006). If we add to this chronic stress an acute stress due to the low pO2 blood concentration and systemic inflammation, all the conditions for a perfect storm are present. My hypothesis is that the disease escapes from the hands of the doctors who are treating it through a fog of molecular mimicry phenomena: antibodies against the viruses might cross-react with epitopes of self-proteins abnormally expressed on the plasma membrane surface of stressed endothelial cells. In turn, these autoimmune reactions against endothelium can generate thrombosis, disseminated intravascular coagulation and multi-organ failure. Surprisingly, to date, no items appear on PubMed or other biomedical search engines if we look for “molecular mimicry” and “COVID-19”. Hence, I would like to strongly encourage researchers and physicians to consider this conjecture among others. In vitro and in vivo studies along with bioinformatic analyses can be used to evaluate this hypothesis.
  5 in total

1.  Endothelial cytotoxicity mediated by serum antibodies to heat shock proteins of Escherichia coli and Chlamydia pneumoniae: immune reactions to heat shock proteins as a possible link between infection and atherosclerosis.

Authors:  M Mayr; B Metzler; S Kiechl; J Willeit; G Schett; Q Xu; G Wick
Journal:  Circulation       Date:  1999-03-30       Impact factor: 29.690

2.  Conformational changes resulting from pseudophosphorylation of mammalian small heat shock proteins--a two-hybrid study.

Authors:  Xiankui Sun; Michael J Welsh; Rainer Benndorf
Journal:  Cell Stress Chaperones       Date:  2006       Impact factor: 3.667

3.  Streptococcal-vimentin cross-reactive antibodies induce microvascular cardiac endothelial proinflammatory phenotype in rheumatic heart disease.

Authors:  F Delunardo; V Scalzi; A Capozzi; S Camerini; R Misasi; M Pierdominici; M Pendolino; M Crescenzi; M Sorice; G Valesini; E Ortona; C Alessandri
Journal:  Clin Exp Immunol       Date:  2013-09       Impact factor: 4.330

Review 4.  Chlamydia trachomatis infection and anti-Hsp60 immunity: the two sides of the coin.

Authors:  Francesco Cappello; Everly Conway de Macario; Valentina Di Felice; Giovanni Zummo; Alberto J L Macario
Journal:  PLoS Pathog       Date:  2009-08-28       Impact factor: 6.823

5.  Human Hsp40 proteins, DNAJA1 and DNAJA2, as potential targets of the immune response triggered by bacterial DnaJ in rheumatoid arthritis.

Authors:  Agnieszka Kotlarz; Stefan Tukaj; Konrad Krzewski; Elzbieta Brycka; Barbara Lipinska
Journal:  Cell Stress Chaperones       Date:  2013-02-14       Impact factor: 3.667

  5 in total
  18 in total

1.  Potential Antiviral Immune Response Against COVID-19: Lessons Learned from SARS-CoV.

Authors:  Laleh Sharifi; Amir Reza Safdarian; Pooya Farhangnia; Mahzad Akbarpour; Mahdis Borjkhani; Nima Rezaei
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

Review 2.  SARS-CoV-2 in patients with cancer: possible role of mimicry of human molecules by viral proteins and the resulting anti-cancer immunity.

Authors:  Stefano Burgio; Everly Conway de Macario; Alberto Jl Macario; Francesco Cappello
Journal:  Cell Stress Chaperones       Date:  2021-05-11       Impact factor: 3.667

3.  SARS-CoV-2 and Guillain-Barré syndrome: molecular mimicry with human heat shock proteins as potential pathogenic mechanism.

Authors:  Guglielmo Lucchese; Agnes Flöel
Journal:  Cell Stress Chaperones       Date:  2020-07-29       Impact factor: 3.667

4.  Does SARS-CoV-2 Trigger Stress-InducedAutoimmunity by Molecular Mimicry? A Hypothesis.

Authors:  Francesco Cappello; Antonella Marino Gammazza; Francesco Dieli; Alberto Jl Macario
Journal:  J Clin Med       Date:  2020-06-29       Impact factor: 4.241

5.  Is molecular mimicry the culprit in the autoimmune haemolytic anaemia affecting patients with COVID-19?

Authors:  Francesca Angileri; Sébastien Légaré; Antonella Marino Gammazza; Everly Conway de Macario; Alberto J L Macario; Francesco Cappello
Journal:  Br J Haematol       Date:  2020-06-08       Impact factor: 6.998

6.  Host Genetics at the Intersection of Autoimmunity and COVID-19: A Potential Key for Heterogeneous COVID-19 Severity.

Authors:  Tugce Karaderi; Halin Bareke; Imge Kunter; Adil Seytanoglu; Ilgin Cagnan; Deniz Balci; Burc Barin; Mevhibe B Hocaoglu; Nilufer Rahmioglu; Esra Asilmaz; Bahar Taneri
Journal:  Front Immunol       Date:  2020-12-22       Impact factor: 7.561

7.  Peptides of H. sapiens and P. falciparum that are predicted to bind strongly to HLA-A*24:02 and homologous to a SARS-CoV-2 peptide.

Authors:  Yekbun Adiguzel
Journal:  Acta Trop       Date:  2021-06-16       Impact factor: 3.112

8.  Neurological involvement of coronavirus disease 2019: a systematic review.

Authors:  Malik Ghannam; Qasem Alshaer; Mustafa Al-Chalabi; Lara Zakarna; Jetter Robertson; Georgios Manousakis
Journal:  J Neurol       Date:  2020-06-19       Impact factor: 4.849

9.  Management of pernio-like cutaneous manifestations in children during the outbreak of COVID-19.

Authors:  Romina Gallizzi; Diana Sutera; Alessandra Spagnolo; Anna Maria Bagnato; Serafinella Patrizia Cannavò; Loredana Grasso; Claudio Guarneri; Giuseppe Nunnari; Francesca Mazza; Giovanni Battista Pajno
Journal:  Dermatol Ther       Date:  2020-10-13       Impact factor: 3.858

10.  Prognostic significance of hemoglobin level and autoimmune hemolytic anemia in SARS-CoV-2 infection.

Authors:  Abdulrahman A Algassim; Assem A Elghazaly; Abdulrahman S Alnahdi; Owais M Mohammed-Rahim; Abdulaziz G Alanazi; Nawaf A Aldhuwayhi; Mashael M Alanazi; Mohammed F Almutairi; Ibrahim M Aldeailej; Najeeb A Kamli; Mahmoud D Aljurf
Journal:  Ann Hematol       Date:  2020-09-12       Impact factor: 3.673

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.